References
- Humphrey MJ, Jevons S, Tarbit MH. Pharmacokinetic evaluation of UK-49,858. a metabolically stable triazole antifungal drug in animals and humans. Antimicrob Agents Chemother 1985; 28: 648–653
- Troke PF, Andrews RJ, Brammer KW, Marriott MS, Richardson K. Efficacy of UK-49.858 (Fluconazole) against Candida albicans experimental infections in mice. Antimicrob Agents Chemother 1985; 28: 815–818
- Taelman H, De Clercq D, Swinne D, De Vroey C. Treatment of candidal and cryptococcal infections with fluconazole in patients with AIDS or ARC. Abstr. European Conference Clin Aspects HIV Infect, Belgium, 1987
- De Wit S, Weerts D, Goossens H, Clumeck N. Comparison of fluconazole and ketoconazole for oropharyngeal candidiasis in AIDS. Lancet 1989; 1: 746–748
- Tavitian A, Raufman J-P, Rosenthal LE, Weber J, Webber CA, Dincsoy HP. Ketoconazole-resistant candida esophagitis in patients with acquired immunodeficiency syndrome. Gastroenterology 1986; 90: 443–445
- Lake-Bakaar G, Tom W, Lake-Bakaar D, Gupta N, Beidas S, Elsakr M, Straus E. Gastropathy and ketoconazole malabsorption in the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 1988; 109: 471–473
- Senior DS, Shaw J TB. In vitro effects of fluconazole (UK-49,858) and ketoconazole on mouse lymphocyte proliferation and on candida blastospore destruction by human polymorphonuclear leukocytes. Int J Immunopharmacol 1988; 10: 169–173